Scinai Immunotherapeutics Ltd (SCNI) is a Healthcare · Biotechnology company listed on NASDAQ. Price $1.56 (-3.70%), Market cap $0.00B, 52-week low–high $0.46 ~ $3.25.
Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis. The company also offers contract development and manufacturing organization services, such as analytical method development, process development, and cGMP manufacturing of clinical-stage materials to early-stage biotechnology companies. It has collaboration pa
Financial statements, price targets, institutional (13F) holdings and related news for Scinai Immunotherapeutics Ltd are updated in real time on BlackAll Trade.
Scinai Immunotherapeutics Ltd trades at $1.56 (-3.70%). Real-time quotes and charts are available on BlackAll Trade.
Scinai Immunotherapeutics Ltd has a market cap of about $0.00B.
Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH